Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
(4) - EconoTimes)
WAYNE, Pa., May 02, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that on May 1, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 3 non-qualified stock option awards to purchase an aggregate of 21,000 shares of its common stock and 8 restricted stock unit awards covering an aggregate of 17,000 shares of its common stock to 8 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of $18.07 per share, which is equal to the closing price of Aclaris' common stock on May 1, 2018. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2017 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Contact
Michael Tung, M.D.
Senior Vice President
Corporate Strategy/Investor Relations
484-329-2140
[email protected]
